Exhib it 99.1 Study 1 Pivotal Phase (1002-040) 3 Long-Term Safety Study Supplemental Materials MAY 8, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-lookin
Tuesday, May 8, 2018 1 min read
Key Takeaway: Study 1 Pivotal Phase (1002-040) 3 Long-Term Safety Study Supplemental Materials MAY 8, 2018
ODYSSEY Outcomes: Alirocumab LDL-C Lowering Wanes Over Time 103.1 Placebo ITT On-treatment* 105 90 75 60 45 30 15 0 101.4 66.4 Alirocumab ITT On-treatment* 53.3 0 4 8 12 16 20 24 28 32 3
Full Press Release Details
Study 1 Pivotal Phase (1002-040) 3 Long-Term Safety Study Supplemental Materials MAY 8, 2018
ODYSSEY Outcomes: Alirocumab LDL-C Lowering Wanes Over Time 103.1 Placebo ITT On-treatment* 105 90 75 60 45 30 15 0 101.4 66.4 Alirocumab ITT On-treatment* 53.3 0 4 8 12 16 20 24 28 32 36 40 44 48 Months Since Randomization *Excludes LDL-C values after premature treatment discontinuation or blinded switch to placebo All LDL-C values, including those after premature treatment discontinuation, blinded down titration, or blinded switch to placebo 28 Mean LDL-C (mg/dL) 93.396.4 48.0 39.8 37.642.3